| Hazard Information | Back Directory | [Uses]
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease[1][2]. | [in vivo]
Mirikizumab (7.5 mg/kg, i.p., administered at 9, 16, and 32 hours) exhibits anti-inflammatory activity in an acute systemic mouse model[2]. | Animal Model: | Acute systemic C57BL/6 mice model | | Dosage: | 7.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), dosing time of 9, 16, 32 h | | Result: | Inhibited human IL-23-induced mouse IL-17A, IL-17F, and keratin-16 mRNA production in an acute systemic mice model. |
| [References]
[1] Jefremow A, et al. Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther. 2020 Nov 26;9:289-297.
[2] Steere B, et al. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. DOI:10.1124/jpet.122.001512 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|